Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Trial Profile

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Heart failure; Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 27 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 21 Apr 2017 Planned End Date changed from 1 Jan 2022 to 1 Jun 2022.
    • 21 Apr 2017 Planned primary completion date changed from 1 Jan 2022 to 1 Jun 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top